<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31226">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02700191</url>
  </required_header>
  <id_info>
    <org_study_id>PCL-72-030</org_study_id>
    <nct_id>NCT02700191</nct_id>
  </id_info>
  <brief_title>Cardiovascular Diagnosis Using µ-Cor - an Interventional Pilot Trial</brief_title>
  <official_title>Cardiovascular Diagnosis Using µ-Cor - an Interventional Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyma Medical Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyma Medical Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects that are being treated at the Congestive Heart Failure clinic in Nazareth will be
      given the µ-Cor system to be added to their standard care, and randomized 1:1 to an
      interventional arm or a control arm.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite of all-cause death or hospitalizations due to heart failure in the Interventional arm compared to the Control arm.</measure>
    <time_frame>30 days to 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>For subjects in the Control arm, the parameters measured by the (µ-Cor) µ-Cor system will not be analysed or made available to the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>uCor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For subjects in the Interventional arm, all of the parameters measured by the (µ-Cor) µ-Cor system will be available to the investigator and will remain blinded to the subjects. The investigator will use µ-Cor information to aid in therapy adjustment decisions during the study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>uCor</intervention_name>
    <arm_group_label>uCor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women 20-90 years old.

          -  New York Heart Association (NYHA) class III-IV heart failure

          -  Followed by the Congestive Heart Failure (CHF) clinic in Nazareth

          -  Left ventricular ejection fraction &lt;35%

          -  Requiring treatment with &gt;40mg/day of furosemide* orally or with repeated bolus or
             intravenous infusion of furosemide* (*or equivalent bumetanide or torasemide).

        Exclusion Criteria:

          -  Pregnancy

          -  Subjects who have received a heart transplant.

          -  Subjects who are unable or unwilling to follow the study requirements.

          -  Patients with allergies or skin sensitivities to electrode hydrogel and/or acrylic
             based adhesive.

          -  Patients with skin breakdown in areas on the chest where device and electrode
             placement is required
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 6, 2016</lastchanged_date>
  <firstreceived_date>March 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
